Finerenone
Cross-source consensus on Finerenone from 1 sources and 4 claims.
1 sources · 4 claims
Uses
Benefits
Evidence quality
Highlighted claims
- Because the study period ended in 2019, nsMRA data are entirely absent from this dataset. — Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China
- Finerenone is currently recommended in the updated Chinese guideline for patients with T2D and CKD who have albuminuria. — Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China
- The CONFIDENCE trial provided prospective data confirming that combining SGLT2i with finerenone slows disease progression and confers long-term organ-protective benefits. — Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China
- Triple combination therapy using SGLT2i, GLP-1 RA, and finerenone has been modelled to produce substantial gains in cardiovascular, kidney, and overall survival. — Clinical characteristics and outcomes of patients with type 2 diabetes mellitus and chronic kidney disease from two new-user medication cohorts: a retrospective cohort study using regional electronic health records database in China